- Home
- NUS vs TRDA Comparison
NUS vs TRDA Comparison
Compare NUS & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUS
- TRDA
- Stock Information
- Founded
- NUS 1984
- TRDA 2016
- Country
- NUS United States
- TRDA United States
- Employees
- NUS N/A
- TRDA N/A
- Industry
- NUS Other Pharmaceuticals
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- NUS Health Care
- TRDA Health Care
- Exchange
- NUS Nasdaq
- TRDA Nasdaq
- Market Cap
- NUS 361.7M
- TRDA 301.0M
- IPO Year
- NUS 1996
- TRDA 2021
- Fundamental
- Price
- NUS $7.77
- TRDA $7.12
- Analyst Decision
- NUS Hold
- TRDA Strong Buy
- Analyst Count
- NUS 2
- TRDA 3
- Target Price
- NUS $6.88
- TRDA $25.67
- AVG Volume (30 Days)
- NUS 574.0K
- TRDA 129.9K
- Earning Date
- NUS 08-07-2025
- TRDA 08-12-2025
- Dividend Yield
- NUS 3.11%
- TRDA N/A
- EPS Growth
- NUS N/A
- TRDA N/A
- EPS
- NUS N/A
- TRDA 0.61
- Revenue
- NUS $1,679,268,000.00
- TRDA $172,220,000.00
- Revenue This Year
- NUS N/A
- TRDA N/A
- Revenue Next Year
- NUS N/A
- TRDA N/A
- P/E Ratio
- NUS N/A
- TRDA $11.74
- Revenue Growth
- NUS N/A
- TRDA 5.74
- 52 Week Low
- NUS $5.32
- TRDA $6.94
- 52 Week High
- NUS $12.65
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- NUS 50.52
- TRDA 36.18
- Support Level
- NUS $7.54
- TRDA $6.94
- Resistance Level
- NUS $8.51
- TRDA $8.49
- Average True Range (ATR)
- NUS 0.28
- TRDA 0.42
- MACD
- NUS -0.10
- TRDA -0.07
- Stochastic Oscillator
- NUS 11.32
- TRDA 10.91
About NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.